A novel DNA vaccine that delivers long lasting immunity by stimulating high avidity CD8 T cells and strong neutralising antibodies

Sancell已经开发出一种快速、低成本和有效的DNA疫苗，这种疫苗可以刺激强大的免疫反应，可以杀死癌细胞，并已被证明对皮肤癌患者的治疗是安全有效的。这种方法还可以用于开发安全有效的疫苗，以防止感染导致新冠肺炎的冠状病毒等病毒。像其他正在开发的疫苗一样，斯坎贝尔的疫苗将帮助人体产生抗体，以阻止新冠肺炎病毒进入细胞并导致人体感染。我们的疫苗与其他方法的不同之处在于，它还将刺激免疫系统产生特殊的T细胞，这种细胞可以识别和杀死可能感染病毒的细胞。这些T细胞也会比抗体在体内停留的时间更长，并在未来感染的情况下留在那里。Sancell已经制造了两种不同的疫苗：SCOV1针对的是最初的武汉毒株，而SCOV2针对的是令人担忧的变种，包括Delta和Omicron。由于英国的所有成年人现在都被提供了新冠肺炎强化注射，斯卡奈尔新冠肺炎疫苗已经在南非的健康志愿者身上接种，那里的疫苗接种率要低得多。Sancell的疫苗是使用一种无针注射装置接种的，这种注射装置易于使用，受到患者和志愿者的喜欢，适合在大流行中使用。评估SCOV1和SCOV2疫苗在健康志愿者中诱导的安全性和免疫反应将使我们能够进入下一阶段在预接种疫苗的志愿者中的研究。

Scancell have developed a fast, low cost and effective DNA vaccine which stimulates potent immune responses that can kill cancer cells and has already been shown to be safe and effective in the treatment of patients with skin cancer. This approach can also be used to develop a safe and effective vaccine to prevent infection with viruses such as the coronavirus that causes COVID-19. Like other vaccines being developed, Scancell’s will help the body to make antibodies to stop the COVID-19 virus getting into cells and causing the person to become infected. What makes our vaccine different from other approaches is that it will also stimulate the immune system to make special T cells that can recognise and kill cells that may have been infected with the virus. These T cells will also remain in the body longer than antibodies and be there in case of future infections. Scancell has made two different vaccines: SCOV1 targets the original Wuhan strain of the virus and SCOV2 targets variant of concern, including Delta and Omicron. As all adults in the UK have now been offered a COVID-19 booster injection, the Scancell COVID-19 vaccines have been administered to healthy volunteers in South Africa where vaccination rates are much lower. Scancell’s vaccines are being given using a needle-free injection device which is easy to use, liked by patients and volunteers, and suitable for use in a pandemic. Evaluation of the safety profile and immune responses induced by the SCOV1 and SCOV2 vaccines in healthy volunteers will allow us to move into the next phase of the study in pre-vaccinated volunteers.